Engineered immune cells take on tough blood cancers in phase 2 trial
NCT ID NCT03642626
First seen Jan 29, 2026 · Last updated Apr 24, 2026 · Updated 10 times
Summary
This study tests FDA-approved CAR-T cell therapy in 150 people with certain blood cancers (acute lymphoblastic leukemia or large B-cell lymphoma) that did not respond to standard treatment or returned. Participants receive their own immune cells that have been reprogrammed to attack cancer. The main goal is to see how many patients achieve complete or partial remission, while monitoring side effects like severe neurological reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.